https://www.businesswire.com/news/home/20190417005971/en/

BURLINGTON, N.C. & EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Apr 17, 2019--LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Envigo, a leading provider of nonclinical contract research services and research models, today announced that LabCorp’s Covance Drug Development segment will acquire Envigo’s nonclinical research services business and Envigo’s Research Models Services business will acquire the Covance Research Products business. This will result in Envigo becoming a pure-play research models and services business, while Covance will expand its global nonclinical drug development capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190417005971/en/